

## Ryaltris<sup>™</sup> (olopatadine/mometasone furoate monohydrate) – New drug approval

- On January 14, 2022, <u>Glenmark Pharmaceuticals announced</u> the <u>FDA approval</u> of <u>Ryaltris</u>
  (<u>olopatadine/mometasone furoate monohydrate</u>), for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.
- The efficacy of Ryaltris was established in two randomized, double-blind, placebo-and active-controlled clinical studies in 2,352 patients 12 years of age and older with seasonal allergic rhinitis. In both studies, patients were randomized to 1 of 4 treatment groups: Ryaltris, olopatadine, mometasone furoate, and vehicle placebo for 2 weeks. The primary endpoint for both studies was the change from baseline in average morning and evening subject reported 12-hour reflective total nasal symptom score (rTNSS) over the 14-day treatment period.
  - In both studies, treatment with Ryaltris resulted in a statistically significant improvement in rTNSS vs. olopatadine and to mometasone furoate as well as to placebo (except for study 1 comparison to mometasone furoate).

	Study 1			Study 2		
	Baseline	Change	Treatment	Baseline	Change	Treatment effect
	mean	from	effect	mean	from	Difference LS
		baseline	Difference LS		baseline LS	mean (95% CI)
		LS mean	mean (95% CI)		mean	
Ryaltris	10.1	-3.5	-	10.1	-3.5	
Olopatadine	10.3	-2.9	-0.6 (-1.0, -0.2)	10.2	-3.1	-0.4 (-0.8, -0.1)
Mometasone	10.2	-3.1	-0.4 (-0.8, 0.0)	10.2	-3.1	-0.5 (-0.9, -0.1)
Placebo	10.2	-2.5	-1.0 (-1.3, -0.6)	10.3	-2.4	-1.1 (-1.5, -0.7)

- Warnings and precautions for Ryaltris include local nasal adverse reactions; somnolence and impaired mental alertness; glaucoma and cataracts; hypersensitivity reactions; immunosuppression and risk of infections; hypercorticism and adrenal suppression; and effect of growth.
- The most common adverse reactions (≥ 1%) with Ryaltris use were dysgeusia, epistaxis, and nasal discomfort.
- The recommended dosage of Ryaltris is 2 sprays (2 sprays deliver a total of 1,330 mcg of olopatadine and 50 mcg of mometasone furoate) in each nostril twice daily.
- Ryaltris will be marketed and distributed through Hikma Specialty and launch plans are pending.
  Ryaltris will be available as a nasal spray delivering 665 mcg of olopatadine and 25 mcg of mometasone furoate in each spray.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.